Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]-olaparib PET; Molecular imaging of DNA damage response by [18F]-olaparib PET
2024-511962-34-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [18f]olaparib in head and neck squamous cell carcinoma (HNSCC), sponsored by University Medical Center Groningen. Planned start Apr 2025; status: authorised.
02
Drugs
[18f]olaparib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-511962-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511962-34-00.